Most of the news reports that focused on this possible silver lining did explain that the effect was only seen in a very small group of the people on the study – though this may not have been clear from some of the headlines people have seen today.
Findings were reported today from the first phase III anti-tau drug in people with mild-to-moderate Alzheimer’s. The drug, called LMTM, was being tested in a 15-month double-blind, controlled trial in 891 people.
Dementia is the most feared diagnosis in the over 55s in the UK, affecting around 850,000 people across the country. You often ask us why some people develop the condition and others don’t, and whether it’s possible to predict who will go on to get dementia.
The immune system is always on the look-out for new problems to deal with, but research is suggesting it may do more harm than good in Alzheimer’s.
This week dementia researchers from six continents, hundreds of research institutions and countless different backgrounds have made their way to Toronto for the world’s largest meeting of dementia researchers – the Alzheimer’s Association International Conference 2016.
To tackle these diseases we need to see research into a range of therapeutic approaches, giving us the best chance of finding effective treatments sooner.
It’s a common misconception that dementia is all about Alzheimer’s and that it’s all about memory loss.
We’re hearing in the news that a new treatment designed to slow Alzheimer’s has shown benefit in one of the final stages of testing in people. So what’s going on?
But why do some people develop the diseases that causes dementia, while others are spared?
The world’s largest dementia conference kicked off in Washington D.C. and we’re proud to be representing the work of Alzheimer’s Research UK on this international stage.